Telemedicine in Oncology: A Permanent Fixture?
Tailoring care in the age of COVID-19, telemedicine rapidly became an integral part of oncology practices. According to a The Cancer Journal study, 87% of oncologists reported positive experiences with virtual visits, envisioning 46% of future interactions via teleconsultation.1 Interestingly, more than 80% of these doctors were new to such technologies pre-pandemic. Patients also praised telemedicine for its accessibility and convenience, with approximately 20% planning to rely entirely on this modality in the future.
However, as we move towards a more hygienic care model, challenges persist. Disparities in technology access remain, posing ongoing hurdles to telehealth’s progression. Alan P. Venook, MD, from UCSF, highlights a downside: the loss of casual yet valuable professional interactions. While telemedicine is here to stay, balancing it with in-person visits is crucial to patient care holism. Future frameworks should consider the financial and infrastructural support critical to telemedicine’s continuity.
Telemedicine: Hedge or Hub?
Rose Grisham, MD, from MSK, notes potential opportunities in democratizing patient access, transcending geographic boundaries. Telemedicine could also revolutionize clinical trial access, facilitating drug distribution while centralizing complex assessments. Yet, current policies supporting telehealth coverage face imminent changes, stirring anxieties about future infrastructures as expressed by Karen McCann, MD, of UCLA Health.
“Right now, Medicare is still covering telemedicine, and other insurance companies are following suit. However, the rules are supposed to change in April, and that’s very concerning,” states McCann. Pivoting to a mixed care model—a telehealth supplement alongside necessary physical visits—serves as a viable, sustainable strategy moving forward.
Delayed Diagnoses: A Lingering Pandemic Consequence
The pandemic’s ripple effects continue in cancer screenings. The Lancet Oncology reports significant screening declines post the national COVID emergency declaration, correlating with cancer underdiagnoses in 2020.3
A study in JAMA noted a rebound in breast and colorectal cancer screenings by 2023, yet cervical cancer screenings lagged, underscoring socioeconomic inequalities persisting post-pandemic.4
Stephanie V. Blank, MD, from Mount Sinai Health System, emphasizes ongoing impacts: “We’re still seeing more advanced cervical cancer than before.” These trends depict a healthcare system that must urgently address delayed cancer presentations and associated complications.
Future Outlook: Screening Strategies
Efforts should focus on restoring confidence in cancer screening among historically underserved populations. Targeted public health campaigns can emphasize the importance of screenings, especially for cervical cancer which still sees declining rates. Innovative community-level interventions could play a pivotal role in reversing these trends.
Long-term COVID Impact on Cancer Patients
Long-term COVID symptoms, such as chronic pulmonary issues, potentially increase lung cancer risks in immunocompromised patients. Research highlighted in Frontiers in Oncology points out that nearly a quarter of cancer patients experiencing “long COVID” show persistent symptoms beyond a year.5
COVID’s long-term inflammation effects pose an additional diagnostic challenge. “Some patients develop chronic inflammation in their lungs post-COVID-19 and later present with lung cancer,” notes Benjamin Herzberg, MD, of Columbia University Medical Center. This phenomenon needs closer scientific scrutiny to understand its full impact on cancer development.
Strategic Antivirus Approaches
For oncologists, particularly addressing therapies in immunocompromised individuals like chronic lymphocytic leukemia (CLL) patients remains crucial. The advent of COVID-19 and its impact on these vulnerable groups compels a cautious approach to immunosuppressive therapies, as illustrated by Greg Roloff, MD, of the University of Chicago Medicine.
Challenge of Clinical Trials and Oncologist Burnout
The pandemic significantly disrupted clinical trials due to logistical hurdles and oncologist burnout. Venook refers to these as major setbacks in oncology advancements. As institutions adapt, some, like City of Hope, highlight EHR interoperability issues that require urgent fixations for improved efficiency.
Ramez N. Eskander, MD, stresses workforce revamping as essential to resuming robust clinical trial operations. “We’ve rebuilt in a dramatic way, and many institutions are following suit,” expresses Eskander, underlining a cautiously optimistic view for near future research infrastructure.
Optimizing Clinical Trial Operations
Adapting systems to address post-pandemic challenges, such as staffing shortages, is crucial. Institutions must continue reforming funding models and enhancing workforce strategies to facilitate trial operations amidst ongoing healthcare pressures. Embracing digital solutions and reevaluating traditional trial frameworks could accelerate these efforts.
Frequently Asked Questions
Q: Will telemedicine indefinitely supplement in-person oncology visits?
A: Yes, while it remains crucial as a supplement, combining telemedicine with occasional in-person visits provides balanced, comprehensive patient care.
Q: Are clinical trials bouncing back post-pandemic?
A: There’s cautious optimism. Institutions have rebuilt their workforce and adapted operations, but challenges persist. Continuous improvement of trial infrastructures and addressing burnout remain pivotal.
Q: How can I stay updated on clinical trial developments?
A: Keep an eye on updates from leading oncology institutions and professional bodies or subscribe to newsletters from oncology-focused organizations to receive regular updates.
Further Reading
To explore more insights into the evolving landscape of oncology care, check out our article on enhancing telehealth accessibility. For updated research on cancer screening trends, visit The Cancer Journal website.
Engage with Us
You’re invited to join the conversation! Share your thoughts or comment below on how telemedicine and clinical trials are evolving in your experience. Don’t forget to subscribe to our newsletter for the latest industry insights and expert analyses!
